艾迪药业(688488.SH)：部分募投项目结项并将节余募集资金永久补充流动资金

Core Viewpoint - The company, Aidi Pharmaceutical (688488.SH), has approved the conclusion of certain fundraising projects and the permanent allocation of surplus funds to supplement its working capital [1] Group 1: Fundraising Projects - The company has decided to conclude the fundraising projects related to the "Innovative Drug R&D and R&D Technology Center Building Purchase Project" specifically for the "Aibond® (Ainovelin Tablets) Phase III Clinical and Post-Marketing Research Project" and the "ACC008 Phase III/IV Clinical Project" [1] - The surplus funds from these projects amount to 28.3095 million yuan and 8.1898 million yuan, respectively, which will be used to permanently supplement the company's working capital [1]